Presentations and Posters
Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Kaho Utsunomiya, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2022.12 SABCS Poster San Antonio, Texas
Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takeshi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
2022.9 ESMO Poster WEB
Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2‐positive primary breast cancer: Neo-LaTH (JBCRG-16) study.
Tomomi Fujisawa, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Eriko Tokunaga, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi
2021.9 ESMO Poster WEB
Genomic profile and response prediction of eribulin mesylate based neoadjuvant chemotherapy in triple negative breast cancer patients
Tomomi Nishimura, Norikazu Masuda, Kosuke Kawaguchi, Masahiro Takada, Yurina Maeshima, Sunao Tanaka, Ravindranath M. Velaga, Yuichiro Kikawa, Takayuki Kadoya, Hiroko Bando, Rikiya Nakamura, Yutaka Yamamoto, Takayuki Ueno, Hiroyuki Yasojima, Hiroshi Ishiguro, Satoshi Morita, Shinji Ohno, Hironori Haga, Seishi Ogawa, Masakazu Toi
2021.9 ESMO Poster WEB
Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer: JBCRG22 TR
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Takayuki Kadoya, Hiroko Bando, Takashi Yamashita, Shoichiro Ohtani, Shigenori Nagai, Takahiro, Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
2021.9 ESMO Poster WEB
Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (Translational Research of the JBCRG-22 Trial)
Kosuke Kawaguchi, Norikazu Masuda, Sunao Tanaka, Hiroko Bando, Tomomi Nishimura, Takayuki Kadoya, Takashi Yamanaka, Shigeru Imoto, Ravindranath M. Velaga, Nobuko Tamura, Tomoyuki Aruga, Yurina Maeshima, Masahiro Takada, Eiji Suzuki, Takayuki Ueno, Seishi Ogawa, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi
2021.9 ESMO Poster WEB
PRECIOUS: Pertuzumab re-treatment for HER2-positive locally advanced/metastatic breast cancer (JBCRG-M05)
Tatsuya Toyama, Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Norikazu Masuda, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Naruto Taira, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
2021.3 JSMO Oral WEB
A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study
Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Japan Breast Cancer Research Group.
2020.12 SABCS Oral WEB
A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with Bevacizumab following fixed cycles of Bevacizumab plus Paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial
Shoichiro Ohtani, Shigehira Saji, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Yutaka Yamamoto, Takashi Ishikawa, Shigenori Nagai, Hiroshi Yoshibayasi, Koji Matsumoto, Yasuaki Sagara, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Norikazu Masuda, Naruto Taira, Satoshi Morita, Shinji Ohno, Masakazu Toi
2020.10 JBCS Oral, WEB
A randomized, phase 2 study of neoadjuvant chemotherapy containing eribulin mesylate for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)
Hiroko Bando, Norikazu Masuda, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R.Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi
2020.9 ESMO Oral WEB
by Voluntary Organization JBCRG